Vimentin (Ser55) Polyclonal Antibody, PE Conjugated

Applications

  • WB
  • FCM

Reactivity

  • Human

Predicted Reactivity

  • Horse
Overview
Catalog # bs-12757R-PE
Product Name Vimentin (Ser55) Polyclonal Antibody, PE Conjugated
Applications WB, FCM
Reactivity Human
Predicted Reactivity Horse
Specifications
Conjugation PE
Host Rabbit
Source KLH conjugated synthesised phosphopeptide derived from human Vimentin around the phosphorylation site of Ser55
Modification Site Ser55
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 7431
Swiss Prot P08670
Subcellular location Cytoplasm
Synonyms Vimentin (phospho S55); p-Vimentin (phospho S55); CTRCT30; Epididymis luminal protein 113; FLJ36605; HEL113; VIM; VIME_HUMAN; vimentin.
Background This gene encodes a member of the intermediate filament family. Intermediate filamentents, along with microtubules and actin microfilaments, make up the cytoskeleton. The protein encoded by this gene is responsible for maintaining cell shape, integrity of the cytoplasm, and stabilizing cytoskeletal interactions. It is also involved in the immune response, and controls the transport of low-density lipoprotein (LDL)-derived cholesterol from a lysosome to the site of esterification. It functions as an organizer of a number of critical proteins involved in attachment, migration, and cell signaling. Mutations in this gene causes a dominant, pulverulent cataract.[provided by RefSeq, Jun 2009]
Application Dilution
WB 1:300-5000
FCM 1:20-100